SLCO2B1 and pancreatic neoplasm: SLCO2B1 expression decreased significantly in pancreatic cancer [27.5 (9.5 to 45) versus 9.1 (5.5 to 12.8); 3.0 fold decrease; P = 0.05] and liver cancer [47.3 (16.1 to 78) versus 17.0 (4.9 to 29); 2.7 fold decrease; P = 0.04].